Heparin Lithium [9045-22-1]

Heparin Lithium salt is an anticoagulant that reversibly binds to antithrombin III (ATIII) and enhances its inhibitory effect on coagulation factors, such as thrombin and factor Xa, significantly enhancing anticoagulant activity.

Heparin Lithium is an effective anticoagulant because it accelerates the rate at which antithrombin inhibits serine proteases in the coagulation cascade.
Heparin Lithium can bind to AT III and thrombin in the ternary complex, increasing the bimolecular rate constant that inhibits thrombin by 2000 times.
Heparin Lithium is thought to function as an anticoagulant primarily through its interaction with AT III by enhancing AT-III-mediated inhibition of clotting factors, including thrombin and factor Xa.
Heparin Lithium is mainly located in tissue mast cell granules closely related to immune response.
Heparin Lithium is subjected to multiple contacts with FGF-2 and FGFR-1 to stabilize FGF-FGFR binding. Heparin Lithium is also in contact with FGFR-1 of adjacent FGF-FGFR complexes, thus appearing to promote FGFR dimerization. [1]

DMSO: < 1 mg/ml (slightly soluble or insoluble)

H2O: 80 mg/mL, Sonication is recommended.